

**Targeting the PI3K/
AKT/mTOR pathway**

**Symposium on Signalling
Pathways in Cancer**
Preliminary programme

Sitges, Barcelona
Spain

28 FEBRUARY - 1 MARCH 2014

IMPORTANT DEADLINES:

13 January 2014 Early registration

05 February 2014 Late registration and pre-registration closure

SYMPOSIUM PRELIMINARY PROGRAMME

Friday, 28 February 2014

14:00/ **Introduction**

14:15 *Fabrice André, Villejuif, France and
Cristiana Sessa, Bellinzona, Switzerland*

MODULE 1: PRINCIPLES OF SIGNAL TRANSDUCTION

14:15/ **The basis of signal transduction**

15:15 *Chair: Andrea Alimonti, Bellinzona, Switzerland*

Introduction to the PI3K pathway
Massimo Brogginì, Milan, Italy

Introduction to the mTOR pathway and protein transduction
George Thomas, Hospitalet de Llobregat, Spain

Q&A

15:15 Coffee break

15:30/ **Pre-clinical data, I**

16:30 *Chair: Andrea Alimonti, Bellinzona, Switzerland*

Pathway interaction with other systems: Growth stimulatory factors, hormonal agents and DNA
Violeta Serra, Barcelona, Spain

PTEN

Andrea Alimonti, Bellinzona, Switzerland

Q&A

16:30/ **Pre-clinical data, II**

17:40 *Chair: Bryan Hennessy, Dublin, Ireland*

Translating preclinics into clinics: Tumour models
Yasir Ibrahim, Barcelona, Spain

Biomarkers in the pre-clinical setting
Bryan Hennessy, Dublin, Ireland

Drug discovery from pre-clinical to phase I
Sylvie Guichard, Macclesfield, UK

Q&A

17:40 **Welcome reception**

Saturday, 01 March 2014

08:30/ **Clinical development of PI3K/AKT/mTOR inhibitors**

10:00 *Chair: Johann de Bono, Sutton, UK*

Distinctive features of the main classes: mTOR, PI3K, dual inhibitors and AKT
Jordi Rodón, Barcelona, Spain

Predictive biomarkers and pharmacodynamics of PI3K/AKT/mTOR inhibitors
Johann de Bono, Sutton, UK

Toxicity and metabolic aspects
Philippe Bedard, Toronto, ON, Canada

Drawbacks and improvements
Cristian Massacesi, Rueil-Malmaison, France

Q&A

10:00 Coffee break

MODULE 2: TARGETING PI3K/AKT/MTOR AXIS IN THE CLINICS

10:20/ **Management of toxicity**

11:20 *Chair: Monica Arnedos, Villejuif, France*

Toxicity of mTOR inhibitors and PI3K
Monica Arnedos, Villejuif, France

Toxicity of combinations
Cristiana Sessa, Bellinzona, Switzerland

Q&A

11:20/ **Breast cancer**

12:30 *Chair: Fabrice André, Villejuif, France*

Efficacy of mTOR inhibition
Thomas Bachelot, Lyon, France

Clinical development of PI3K
Cristina Saura, Barcelona, Spain

Rationale for combination strategies
Fabrice André, Villejuif, France

Combinations with chemotherapy
Sibylle Loibl, Neu-Isenburg, Germany

Q&A

12:30 Lunch

13:15/ **GU cancers**

14:05 *Chair: James Larkin, London, UK*

Renal
James Larkin, London, UK

Prostate
Christophe Massard, Villejuif, France

Q&A

14:05/ **Other tumours**

15:30 *Chair: Fortunato Ciardiello, Naples, Italy*

Lymphoma
Anastasios Stathis, Bellinzona, Switzerland

pNET
Marianne Pavel, Berlin, Germany

Lung
Fortunato Ciardiello, Naples, Italy

Gynaecological - endometrial
Cristiana Sessa, Bellinzona, Switzerland

Q&A

15:30/ **Take home messages and closing remarks**

16:00 *Fabrice André, Villejuif, France and
Cristiana Sessa, Bellinzona, Switzerland*

Contacts and organisation

ESMO Head Office

Via Luigi Taddei 4
6962 Viganello-Lugano
Switzerland

Organisation and Travel grants

Barbara Magri

Tel. +41 (0)91 973 19 62
Fax +41 (0)91 973 19 18
symposia@esmo.org

Sponsorship and Industry Relations

Nikolaj Tomma

Tel. +41 (0)91 973 19 90
Fax +41 (0)91 973 19 05
marketing@esmo.org

Scientific programme

Kate Kronig

Tel. +41 (0)91 973 19 19
Fax +41 (0)91 973 19 18
programme@esmo.org

Media relations

Vanessa Pavinato

Tel. +41 (0)91 973 19 07
Fax +41 (0)91 973 19 93
media@esmo.org

Registration

Nicole Bullo

Tel. +41 (0)91 973 19 39
Fax +41 (0)91 973 19 18
registration@esmo.org

For frequent updates,
please visit **esmo.org**